Lukas Biomedical｜The Best Choice For Cell Therapy

Through patented high-tech cell culture technology, the concentration of T cells can reach over 95%, equivalent to nearly ten billion high-quality T cells, enabling them to effectively destroy cancer cells within the human body for a long period.

The memory T cell culture technology originates from Japan's National Cancer Research Center, where Phase III clinical trials have been completed. The technology was transferred to South Korea, where Phase III clinical trials were also completed. It has received drug approval and been marketed in South Korea. Up to Phase IV clinical trials, the technology has accumulated over 10,000 clinical treatment cases in Japan and South Korea.

At qualified medical institutions, doctors evaluate and examine patients and draw blood samples to isolate immune cells. Using Lukas Biomedical's patented cell expansion and culture technology, the number of memory T cells can reach 109 to 1010 within 2-3 weeks, with a maximum expansion of nearly ten billion cells. These cells are then reinfused into the patient by doctors at the hospital. This treatment helps cancer patients maintain a good quality of life with fewer side effects and lower drug resistance.

Memory T cells have a long lifespan in the body and can continuously patrol, recognize, and attack cancer cells, effectively reducing the risk of cancer recurrence.

With immune memory, specificity, a long lifespan, and the ability to reactivate upon cancer recurrence, memory T cells help reduce the risk of recurrence.

Memory T cells serve as a long-lasting anti-cancer weapon, with the ability to self-differentiate and proliferate, effectively reducing the risk of cancer recurrence.